Jpmorgan Chase & CO Lantern Pharma Inc. Transaction History

Jpmorgan Chase & CO

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Dec 26, 2024	BUY	$2.48 - $4.39 $32 - $57	13 New	13 $0
Q4 2023 Feb 12, 2024	BUY	$2.48 - $4.39 $9 - $17	4 Added 44.44%	13 $0
Q3 2023 Nov 14, 2023	BUY	$3.41 - $5.51 $30 - $49	9 New	9 $0
Q3 2022 Nov 14, 2022	SELL	$4.59 - $6.5 $8,991 - $12,733	-1,959 Reduced 52.3%	1,787 $9,000
Q2 2022 Aug 11, 2022	SELL	$4.82 - $7.45 $20,591 - $31,826	-4,272 Reduced 53.28%	3,746 $21,000
Q1 2022 May 11, 2022	BUY	$5.6 - $8.22 $15,500 - $22,752	2,768 Added 52.72%	8,018 $57,000
Q4 2021 Feb 10, 2022	BUY	$7.11 - $11.04 $37,327 - $57,959	5,250 New	5,250 $42,000

1.28M

39.8K

6.1K

Ticker LTRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 10,830,900
Market Cap $54.2M
Description
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-30...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.